The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.
LIFE-BTK trial was designed as a superiority trial. The investigators randomly assigned 261 people 2:1 to Esprit or PTA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback